Lagarde Michel 4
4 · THERMO FISHER SCIENTIFIC INC. · Filed Dec 4, 2025
Insider Transaction Report
Form 4
Lagarde Michel
Executive Vice President
Transactions
- Exercise/Conversion
Common Stock
2025-12-02$105.17/sh+36,000$3,786,120→ 59,479.909 total - Sale
Common Stock
2025-12-02$581.92/sh−30,000$17,457,600→ 29,479.909 total - Exercise/Conversion
Common Stock
2025-12-03$105.17/sh+68,000$7,151,560→ 97,479.909 total - Sale
Common Stock
2025-12-03$583.33/sh−29,479$17,195,985→ 68,000.909 total - Sale
Common Stock
2025-12-03$584.11/sh−2,521$1,472,541→ 65,479.909 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-02−36,000→ 86,637 totalExercise: $105.17Exp: 2026-07-20→ Common Stock (36,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-03−68,000→ 18,637 totalExercise: $105.17Exp: 2026-07-20→ Common Stock (68,000 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.90 to $582.33, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.03 to $583.96, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.00 to $584.533, inclusive.
- [F4]The option vested in two equal installments on August 29, 2017 and 2020.